Digital Pathology Market: Global and Regional Analysis with Forecast till 2028, Business Opportunities, Post COVID Scenario

According to the report, the global Digital Pathology market size was valued at $502.3 Million in 2020 and is expected to reach $1,759.80 Million by 2028 growing at the CAGR of 16.78% from 2021 to 2028. This growth is attributed to the low cost of digital pathology goods, the convenience of virtual slide transmission, and the high efficiency of digital pathology systems are the primary reasons driving the global digital pathology market forward. However, the expansion of the digital pathology sector is hampered by confusing payment regulations, a scarcity of experienced employees, and the hesitation of older pathologists to adopt new technologies. Furthermore, the growing number of projects aimed at commercializing low-cost digital pathology systems is expected to generate attractive growth opportunities for service providers.

Request Free Sample Report or PDF Copy: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=005434

The recently published research report on the Global Digital Pathology Market by Evolve Business Intelligence examines the industry in the context of major market aspects including market size & forecast, market shares in terms of revenues and volume, key players, and SWOT analysis. The market is analyzed based on 4 separate indications in the market dynamic chapter: Drivers, Restraints, Key Trends, and Challenges. The total sum of these sections will help you understand what strategies will be best to adopt in order to prosper through this industry over a few short years. The quantitative analysis includes our actual findings out of this research study where we provided additional insight into what our readers can do to embrace new opportunities or plan against threats that might hinder the market.

The COVID-19 pandemic has led to disruption in the supply chain leading to lower demand or supply shortages in the Digital Pathology market. The travel restrictions and social-distancing measures have resulted in a sharp drop in consumer and business spending and this pattern is expected to continue for some time. The end-user trend and preferences have changed due to the pandemic and have resulted in manufacturers, developers, and service providers adopting various strategies to stabilize the company.

The New Normal
As businesses recover from the COVID-19 pandemic, they have a new set of priorities to cope with. Throughout this crisis, they were forced to deal with shifting situations and often fell short of their ultimate goals. Now that a cure has been found and the pandemic is dying down, they will need to recuperate from this epidemic by setting forth new objectives to succeed in the future.

In terms of COVID 19 impact, the Digital Pathology market report also includes the following data points:
• COVID19 Impact on Digital Pathology market size
• End-User/Industry/Application Trend, and Preferences
• Government Policies/Regulatory Framework
• Key Players Strategy to Tackle Negative Impact/Post-COVID Strategies
• Opportunity in the Digital Pathology market

Buy Latest Copy of Report Now at Higher Discount: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=005434

Key Players
Some of the major Digital Pathology players holding high market share include company Leica Biosystems, Koninklijke Philips, Hamamatsu Photonics K.K, Roche. These players use new product development and collaboration as a key strategy to gain significant market share to compete with market leaders.

The key players profiled in the report are:
• Leica Biosystems
• Koninklijke Philips N.V.
• Hamamatsu Photonics K.K
• Roche
• 3DHISTECH
• Apollo Enterprise Imaging
• XIFIN
• Huron Digital Pathology
• Visiopharm A/S
• Corista

Segmental Analysis
Market Segment By Product Type with focus on market share, consumption trend, and growth rate of Digital Pathology Market:
o Scanners
o Software
o Others

Market Segment By Application with focus on market share, consumption trend, and growth rate of Digital Pathology Market:
o Drug Discovery
o Disease Diagnosis
o Teleconsultation
o Training & Education

Market Segment By End User with a focus on market share, consumption trend, and growth rate of Digital Pathology Market:
o Pharmaceutical & Biotechnology Companies
o Hospitals and Reference Laboratories
o Academic & Research Institutes

For more information: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=005434

Global Digital Pathology Geographic Coverage:
• North America
o US
o Canada
o Mexico

• Europe
o UK
o Germany
o France
o Italy
o Rest of Europe

• Asia Pacific
o China
o Japan
o India
o South Korea
o Rest of Asia Pacific

• Rest of the World
o South America
o Middle East & Africa

North America held the highest proportion of the digital pathology market. The rising prevalence of cancer, rising demand for quality diagnostics, the introduction of favorable economic policies, and the integration of favorable government policies in the US and Canada are all factors contributing to this region's large share of the global digital pathology market.

Address
Evolve Business Intelligence
C-218, 2nd floor, M-Cube
Gujarat 396191
India
Contact: +1 773 644 5507 / +91 635 396 3987
Email: sales@evolvebi.com
Website: https://evolvebi.com/

About EvolveBI
Evolve Business Intelligence is market research, business intelligence, and advisory firm providing innovative solutions to challenging pain points of a business. Our market research reports include data useful to micro, small, medium, and large-scale enterprises. We provide solutions ranging from mere data collection to business advisory.
Evolve Business Intelligence is built on account of technology advancement providing highly accurate data through our in-house AI-modelled data analysis and forecast tool – EvolveBI. This tool tracks real-time data including, quarter performance, annual performance, and recent developments from fortune’s global 2000 companies.

This release was published on openPR.